Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
|Articles|February 25, 2013
A Complex Role for Medicare in the Standoff in Washington
Advertisement
WASHINGTON — In some ways, the partisan standoff over looming budget cuts resembles earlier links in the chain of fiscal battles that began two years ago.
But the politics of one core dispute between Democrats and Republicans — what to do about Medicare — are changing. And some of those changes complicate President Obama’s agenda, even as he continues to flex his postelection muscle.
Read the full story:
Source: The New York Times
Advertisement
Related to this article
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
5